Prof. Eric Haaksma
Prof. Eric Haaksma on transforming lives for generations
Search
Human Health
Human Health
Liliana Montano
Liliana Montano on constant innovation
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Sales consultant about working with purpose
Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Introduction to head-to-head trials
Hear from experts Dr Kerr and Dr Melosky.
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Brigimadlin
MDM2-p53 antagonist
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
A Clear Vision
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Ridgefield
Ridgefield is home to the company’s US headquarters. The site serves as a key research center for human pharmaceuticals.